The performance of Requip in the treatment of Parkinson's disease was reviewed in a multinational drug advancement program containing 11 randomized, controlled trials. Four tests were carried out in people with early Parkinson's disease and no concomitant levodopa (L-dopa) and 7 trials were performed in people with state-of-the-art Parkinson's condition with concomitant L-dopa.
3 placebo‑controlled trials offer evidence of performance of Requip in the administration of patients with Parkinson's illness that were and were not obtaining concomitant L-dopa. Two of these three trials enlisted patients with very early Parkinson's illness (without L-dopa) and one registered patients obtaining L-dopa.
In these tests a selection of actions were utilized to examine the results of therapy (e. g. the Unified Parkinson's Disease Rating Scale [UPDRS], Clinical Global Impression [CGI] ratings, person daily records recording time "on" and "off," tolerability of L-dopa dose decreases).
In both trials of patients with early Parkinson's illness (without L-dopa), the electric motor part (Part III) of the UPDRS was the key end result evaluation. The UPDRS is a multi-item score scale planned to review mentation (Part I), activities of daily living (Part II), electric motor efficiency (Part III), and also difficulties of treatment (Part IV). Part III of the UPDRS has 14 items made to assess the severity of the primary electric motor searchings for in people with Parkinson's condition (e. g. tremor, rigidity, bradykinesia, postural instability) racked up for various physical body regions as well as has an optimum (worst) score of 108. In the trial of clients with innovative Parkinson's condition (with L-dopa), both decrease in percent awake time spent "off" and the capability to lower the everyday use of L-dopa were evaluated as a combined endpoint and also independently.